9 results on '"Bartlett,John"'
Search Results
2. Contemporary indications for psychosurgery.
- Author
-
Bartlett, John, Bridges, Paul, Kelly, Desmond, Bartlett, J, Bridges, P, and Kelly, D
- Subjects
PSYCHOSURGERY ,BRAIN surgery ,MENTAL health services ,MENTAL illness ,MENTAL depression ,PSYCHOLOGICAL stress ,ANXIETY ,AFFECTIVE disorders ,OBSESSIVE-compulsive disorder ,PERSONALITY ,PROGNOSIS ,SCHIZOPHRENIA - Abstract
The article focuses on the indications for surgical treatment of certain psychiatric illnesses in modern days. In Great Britain, there were 431 psychosurgical operations were carried out from different hospital units between 1974 and 1976. The diagnosis revealed that 63% of patients has refractory depressive illnesses, 12% suffered from anxiety, tension, and phobic states, 7% suffered from severe obsessional illness, and 6% has schizophrenic. Meanwhile, data from the U.S. and Canada revealed numerous operations between 1971 and 1974. With the emergence of technology, extensive lesion of prefrontal leucotomy had multiple effects to people with schizophrenia and excellent outcomes of affective disorders.
- Published
- 1981
- Full Text
- View/download PDF
3. CORRESPONDENCE.
- Author
-
Lambden, Paul, Yellowless, Henry, Powell, D.E.B., Stevenson, John S., Garrow, John, Hornsby, Beve, Krakauer, R., Duncan, Garry W., Pessin, Michael, Mohr, J.P., Warner, T.F.C.S., Watson-Baker, H.R., Girdwood, T.G., Scott-Harden, W.G., Bartlett, John, Dreysdale, H.C., Hellier, Michael D., and Witherspoon, E.W.
- Subjects
MEDICINE ,COCAINE ,BREAST cancer - Abstract
Reports several medical correspondence from the October 1978 issue of the 'British Medical Journal.' Information on the worldwide shortage of cocaine; Reactions of polyoxyethylated castor oil to the intravenous induction agent; Analysis on female patients with carcinoma of the breast.
- Published
- 1978
4. CORRESPONDENCE .
- Author
-
Sutherland, David C., Rea, Harold H., Grant, Ian W.B., Slessor, I.M., Martin, G.J., Prior, J.G., Anderson, J.B., James, P.N.E., Cochrane, G.M., Sharr, Michael M., Neil-Dwyer, G., Bartlett, John R., Honigsberger, L., Fielding, J.W., Priestman, T.J., Inman, W.H.W., Kersey, P.J.W., and Caldwell, I.
- Subjects
MEDICINE ,ASTHMA treatment ,IMMUNOGLOBULINS ,NEUROSURGERY - Abstract
Comments on several medical related topics. Records on the treatment of asthma in New Zealand; Availability of neurological units for the treatment of spinal and cerebral tumors in the National Health Service in Great Britain; Use of prophylactic antibodies in neurosurgery.
- Published
- 1983
5. Smart cards for construction: CSCS update.
- Author
-
Bartlett, John
- Subjects
- *
CERTIFICATION , *CONSTRUCTION industry - Abstract
The article presents a reader's view on the non-issuance of competence cards under the Construction Skills Certification Scheme (CSCS) in Great Britain.
- Published
- 2014
6. Sign of the times - common courtesy.
- Author
-
James, Ron, Stammers, Adrian, and Bartlett, John
- Subjects
EMPLOYERS' liability ,GOVERNMENT liability - Abstract
Several letters to the editor are presented in response to the article related to employers' and public liability claims in Great Britain when there is no record of an incident.
- Published
- 2014
7. Image-based multiplex immune profiling of cancer tissues: translational implications. A report of the International Immuno-oncology Biomarker Working Group on Breast Cancer.
- Author
-
Jahangir CA, Page DB, Broeckx G, Gonzalez CA, Burke C, Murphy C, Reis-Filho JS, Ly A, Harms PW, Gupta RR, Vieth M, Hida AI, Kahila M, Kos Z, van Diest PJ, Verbandt S, Thagaard J, Khiroya R, Abduljabbar K, Acosta Haab G, Acs B, Adams S, Almeida JS, Alvarado-Cabrero I, Azmoudeh-Ardalan F, Badve S, Baharun NB, Bellolio ER, Bheemaraju V, Blenman KR, Botinelly Mendonça Fujimoto L, Burgues O, Chardas A, Cheang MCU, Ciompi F, Cooper LA, Coosemans A, Corredor G, Dantas Portela FL, Deman F, Demaria S, Dudgeon SN, Elghazawy M, Fernandez-Martín C, Fineberg S, Fox SB, Giltnane JM, Gnjatic S, Gonzalez-Ericsson PI, Grigoriadis A, Halama N, Hanna MG, Harbhajanka A, Hart SN, Hartman J, Hewitt S, Horlings HM, Husain Z, Irshad S, Janssen EA, Kataoka TR, Kawaguchi K, Khramtsov AI, Kiraz U, Kirtani P, Kodach LL, Korski K, Akturk G, Scott E, Kovács A, Laenkholm AV, Lang-Schwarz C, Larsimont D, Lennerz JK, Lerousseau M, Li X, Madabhushi A, Maley SK, Manur Narasimhamurthy V, Marks DK, McDonald ES, Mehrotra R, Michiels S, Kharidehal D, Minhas FUAA, Mittal S, Moore DA, Mushtaq S, Nighat H, Papathomas T, Penault-Llorca F, Perera RD, Pinard CJ, Pinto-Cardenas JC, Pruneri G, Pusztai L, Rajpoot NM, Rapoport BL, Rau TT, Ribeiro JM, Rimm D, Vincent-Salomon A, Saltz J, Sayed S, Hytopoulos E, Mahon S, Siziopikou KP, Sotiriou C, Stenzinger A, Sughayer MA, Sur D, Symmans F, Tanaka S, Taxter T, Tejpar S, Teuwen J, Thompson EA, Tramm T, Tran WT, van der Laak J, Verghese GE, Viale G, Wahab N, Walter T, Waumans Y, Wen HY, Yang W, Yuan Y, Bartlett J, Loibl S, Denkert C, Savas P, Loi S, Specht Stovgaard E, Salgado R, Gallagher WM, and Rahman A
- Subjects
- Humans, Female, Biomarkers, Tumor genetics, Prognosis, Phenotype, United Kingdom, Tumor Microenvironment, Breast Neoplasms
- Abstract
Recent advances in the field of immuno-oncology have brought transformative changes in the management of cancer patients. The immune profile of tumours has been found to have key value in predicting disease prognosis and treatment response in various cancers. Multiplex immunohistochemistry and immunofluorescence have emerged as potent tools for the simultaneous detection of multiple protein biomarkers in a single tissue section, thereby expanding opportunities for molecular and immune profiling while preserving tissue samples. By establishing the phenotype of individual tumour cells when distributed within a mixed cell population, the identification of clinically relevant biomarkers with high-throughput multiplex immunophenotyping of tumour samples has great potential to guide appropriate treatment choices. Moreover, the emergence of novel multi-marker imaging approaches can now provide unprecedented insights into the tumour microenvironment, including the potential interplay between various cell types. However, there are significant challenges to widespread integration of these technologies in daily research and clinical practice. This review addresses the challenges and potential solutions within a structured framework of action from a regulatory and clinical trial perspective. New developments within the field of immunophenotyping using multiplexed tissue imaging platforms and associated digital pathology are also described, with a specific focus on translational implications across different subtypes of cancer. © 2024 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland., (© 2024 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.)
- Published
- 2024
- Full Text
- View/download PDF
8. Breast cancer biomarkers in clinical testing: analysis of a UK national external quality assessment scheme for immunocytochemistry and in situ hybridisation database containing results from 199 300 patients.
- Author
-
Dodson A, Parry S, Ibrahim M, Bartlett JM, Pinder S, Dowsett M, and Miller K
- Subjects
- Biomarkers, Tumor genetics, Breast Neoplasms genetics, Breast Neoplasms metabolism, Breast Neoplasms pathology, Databases, Factual, Estrogen Receptor alpha genetics, Female, Humans, Immunohistochemistry, In Situ Hybridization, Ireland, Receptor, ErbB-2 genetics, Receptors, Progesterone genetics, United Kingdom, Biomarkers, Tumor metabolism, Breast Neoplasms diagnosis, Estrogen Receptor alpha metabolism, Receptor, ErbB-2 metabolism, Receptors, Progesterone metabolism
- Abstract
We describe a collated data set of results from clinical testing of breast cancers carried out between 2009 and 2016 in the United Kingdom and Republic of Ireland. More than 199 000 patient biomarker data sets, together with clinicopathological parameters were collected. Our analyses focused on human epidermal growth factor receptor-2 (HER2), oestrogen receptor (ER) and progesterone receptor (PR), with the aim of the study being to provide robust confirmatory evidence on known associations in these biomarkers and to uncover new data on previously undescribed or unconfirmed associations, thus strengthening the evidence-base in clinical breast cancer testing. Overall, 13.1% of tumours were HER2-positive; 10.6% in ER-positive tumours, and 25.5% in ER-negative tumours. Higher rates of HER2 positivity were significantly associated with patient age <56 years versus age ≥56 years, symptomatic versus screen-detected tumours, testing of involved axillary node versus primary breast cancer, invasive ductal carcinoma (not otherwise specified) versus other histological types, higher histological grade, increasing tumour size, increasing nodal involvement, ER-negative versus ER-positive tumour status, PR-negative versus PR-positive tumour status. Where ER status was known, 82.7% of tumours were ER-positive; 80.9% in women age <56 years, and 83.6% in those age ≥56 years (ER-positive cut-off ≥1.0% positive tumour cells or equivalent). Where PR status was known, 64.9% of tumours were PR-positive; 65.8% in women age <56 years, and 64.4% in women age ≥56 years (PR-positive cut off ≥10.0% or equivalent). These analyses of clinical test results provide contemporary benchmarking data for HER2, ER and PR positive rates., (© 2018 The Authors. The Journal of Pathology: Clinical Research published by The Pathological Society of Great Britain and Ireland and John Wiley & Sons Ltd.)
- Published
- 2018
- Full Text
- View/download PDF
9. OPTIMA prelim: a randomised feasibility study of personalised care in the treatment of women with early breast cancer.
- Author
-
Stein RC, Dunn JA, Bartlett JM, Campbell AF, Marshall A, Hall P, Rooshenas L, Morgan A, Poole C, Pinder SE, Cameron DA, Stallard N, Donovan JL, McCabe C, Hughes-Davies L, and Makris A
- Subjects
- Adult, Feasibility Studies, Female, Humans, Middle Aged, Neoplasm Recurrence, Local, Prognosis, Receptor, ErbB-2, Receptors, Estrogen, Research Design, United Kingdom, Breast Neoplasms drug therapy, Chemotherapy, Adjuvant methods
- Abstract
Background: There is uncertainty about the chemotherapy sensitivity of some oestrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancers. Multiparameter assays that measure the expression of several tumour genes simultaneously have been developed to guide the use of adjuvant chemotherapy for this breast cancer subtype. The assays provide prognostic information and have been claimed to predict chemotherapy sensitivity. There is a dearth of prospective validation studies. The Optimal Personalised Treatment of early breast cancer usIng Multiparameter Analysis preliminary study (OPTIMA prelim) is the feasibility phase of a randomised controlled trial (RCT) designed to validate the use of multiparameter assay directed chemotherapy decisions in the NHS., Objectives: OPTIMA prelim was designed to establish the acceptability to patients and clinicians of randomisation to test-driven treatment assignment compared with usual care and to select an assay for study in the main RCT., Design: Partially blinded RCT with adaptive design., Setting: Thirty-five UK hospitals., Participants: Patients aged ≥ 40 years with surgically treated ER-positive HER2-negative primary breast cancer and with 1-9 involved axillary nodes, or, if node negative, a tumour at least 30 mm in diameter., Interventions: Randomisation between two treatment options. Option 1 was standard care consisting of chemotherapy followed by endocrine therapy. In option 2, an Oncotype DX(®) test (Genomic Health Inc., Redwood City, CA, USA) performed on the resected tumour was used to assign patients either to standard care [if 'recurrence score' (RS) was > 25] or to endocrine therapy alone (if RS was ≤ 25). Patients allocated chemotherapy were blind to their randomisation., Main Outcome Measures: The pre-specified success criteria were recruitment of 300 patients in no longer than 2 years and, for the final 150 patients, (1) an acceptance rate of at least 40%; (2) recruitment taking no longer than 6 months; and (3) chemotherapy starting within 6 weeks of consent in at least 85% of patients., Results: Between September 2012 and 3 June 2014, 350 patients consented to join OPTIMA prelim and 313 were randomised; the final 150 patients were recruited in 6 months, of whom 92% assigned chemotherapy started treatment within 6 weeks. The acceptance rate for the 750 patients invited to participate was 47%. Twelve out of the 325 patients with data (3.7%, 95% confidence interval 1.7% to 5.8%) were deemed ineligible on central review of receptor status. Interviews with researchers and recordings of potential participant consultations made as part of the integral qualitative recruitment study provided insights into recruitment barriers and led to interventions designed to improve recruitment. Patient information was changed as the result of feedback from three patient focus groups. Additional multiparameter analysis was performed on 302 tumour samples. Although Oncotype DX, MammaPrint(®)/BluePrint(®) (Agendia Inc., Irvine, CA, USA), Prosigna(®) (NanoString Technologies Inc., Seattle, WA, USA), IHC4, IHC4 automated quantitative immunofluorescence (AQUA(®)) [NexCourse BreastTM (Genoptix Inc. Carlsbad, CA, USA)] and MammaTyper(®) (BioNTech Diagnostics GmbH, Mainz, Germany) categorised comparable numbers of tumours into low- or high-risk groups and/or equivalent molecular subtypes, there was only moderate agreement between tests at an individual tumour level (kappa ranges 0.33-0.60 and 0.39-0.55 for tests providing risks and subtypes, respectively). Health economics modelling showed the value of information to the NHS from further research into multiparameter testing is high irrespective of the test evaluated. Prosigna is currently the highest priority for further study., Conclusions: OPTIMA prelim has achieved its aims of demonstrating that a large UK clinical trial of multiparameter assay-based selection of chemotherapy in hormone-sensitive early breast cancer is feasible. The economic analysis shows that a trial would be economically worthwhile for the NHS. Based on the outcome of the OPTIMA prelim, a large-scale RCT to evaluate the clinical effectiveness and cost-effectiveness of multiparameter assay-directed chemotherapy decisions in hormone-sensitive HER2-negative early breast would be appropriate to take place in the NHS., Trial Registration: Current Controlled Trials ISRCTN42400492., Funding: This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full in Health Technology Assessment; Vol. 20, No. 10. See the NIHR Journals Library website for further project information. The Government of Ontario funded research at the Ontario Institute for Cancer Research. Robert C Stein received additional support from the NIHR University College London Hospitals Biomedical Research Centre.
- Published
- 2016
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.